Do analysts prefer BCAB or CPHI?

BioAtla currently has a consensus price target of $200.00, indicating a potential upside of 4,673.27%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BCAB or CPHI more profitable?

BioAtla has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. BioAtla's return on equity of 0.00% beat China Pharma's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% China Pharma -85.56% -63.93% -31.42%

Is BCAB or MDCX more profitable?

BioAtla's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Medicus Pharma N/A -3,137.84% -311.33%

Is TVGN or BCAB more profitable?

Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% BioAtla N/A N/A -325.64%

Is BCAB or SKYE more profitable?

BioAtla's return on equity of 0.00% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Skye Bioscience N/A -217.27% -162.39%

BioAtla (BCAB) Competitors

$4.19 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.07 -0.12 (-2.89%)

As of 07/2/2026 07:57 PM Eastern

Compare

BCAB vs. CPHI, MDCX, TVGN, SKYE, and MRKR

Should you buy BioAtla stock or one of its competitors? MarketBeat compares BioAtla with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAtla include China Pharma (CPHI), Medicus Pharma (MDCX), Tevogen Bio (TVGN), Skye Bioscience (SKYE), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.

How does BioAtla compare to China Pharma?

BioAtla (NASDAQ:BCAB) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

China Pharma has higher revenue and earnings than BioAtla. China Pharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A
China Pharma	$3.99M	7.29	-$3.08M	-$0.55	N/A

BioAtla has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. BioAtla's return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
China Pharma	-85.56%	-63.93%	-31.42%

BioAtla has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

BioAtla currently has a consensus price target of $200.00, indicating a potential upside of 4,673.27%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

77.2% of BioAtla shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 6.4% of China Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BioAtla's average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
China Pharma	Neutral

Summary

BioAtla beats China Pharma on 8 of the 14 factors compared between the two stocks.

How does BioAtla compare to Medicus Pharma?

BioAtla (NASDAQ:BCAB) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Medicus Pharma has lower revenue, but higher earnings than BioAtla. Medicus Pharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

BioAtla's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Medicus Pharma	N/A	-3,137.84%	-311.33%

77.2% of BioAtla shares are held by institutional investors. 9.3% of BioAtla shares are held by insiders. Comparatively, 8.1% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioAtla has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

In the previous week, Medicus Pharma had 2 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Medicus Pharma and 0 mentions for BioAtla. Medicus Pharma's average media sentiment score of 0.61 beat BioAtla's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
BioAtla	Neutral
Medicus Pharma	Positive

BioAtla presently has a consensus price target of $200.00, indicating a potential upside of 4,673.27%. Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,061.90%. Given BioAtla's higher possible upside, equities analysts clearly believe BioAtla is more favorable than Medicus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

BioAtla and Medicus Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does BioAtla compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Tevogen Bio had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for BioAtla. Tevogen Bio's average media sentiment score of 0.67 beat BioAtla's score of 0.00 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Tevogen Bio	Positive
BioAtla	Neutral

77.2% of BioAtla shares are held by institutional investors. 70.5% of Tevogen Bio shares are held by insiders. Comparatively, 9.3% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tevogen Bio has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Tevogen Bio has higher earnings, but lower revenue than BioAtla. Tevogen Bio is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 1,633.10%. BioAtla has a consensus price target of $200.00, suggesting a potential upside of 4,673.27%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Tevogen Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
BioAtla	N/A	N/A	-325.64%

Summary

BioAtla beats Tevogen Bio on 8 of the 13 factors compared between the two stocks.

How does BioAtla compare to Skye Bioscience?

BioAtla (NASDAQ:BCAB) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

BioAtla's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Skye Bioscience	N/A	-217.27%	-162.39%

In the previous week, Skye Bioscience had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for BioAtla. BioAtla's average media sentiment score of 0.00 equaled Skye Bioscience'saverage media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
Skye Bioscience	Neutral

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 4,673.27%. Skye Bioscience has a consensus target price of $8.50, suggesting a potential upside of 1,113.42%. Given BioAtla's higher probable upside, research analysts clearly believe BioAtla is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Skye Bioscience has lower revenue, but higher earnings than BioAtla. Skye Bioscience is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A

BioAtla has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.94, indicating that its share price is 194% more volatile than the broader market.

77.2% of BioAtla shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 9.3% of BioAtla shares are held by insiders. Comparatively, 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Skye Bioscience beats BioAtla on 8 of the 14 factors compared between the two stocks.

How does BioAtla compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 9.3% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 580.27%. BioAtla has a consensus price target of $200.00, indicating a potential upside of 4,673.27%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. BioAtla's return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
BioAtla	N/A	N/A	-325.64%

In the previous week, Marker Therapeutics had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Marker Therapeutics and 0 mentions for BioAtla. Marker Therapeutics' average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Marker Therapeutics	Neutral
BioAtla	Neutral

Marker Therapeutics has higher earnings, but lower revenue than BioAtla. Marker Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	N/A	N/A	-$12.16M	-$0.61	N/A
BioAtla	$2M	3.48	-$59.61M	-$41.72	N/A

Marker Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Summary

Marker Therapeutics and BioAtla tied by winning 7 of the 14 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.94M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.10	21.61	28.02	24.70
Price / Sales	3.48	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-0.15	8.66	10.96	6.46
Net Income	-$59.61M	$23.81M	$3.57B	$337.01M
7 Day Performance	13.86%	3.39%	2.12%	1.69%
1 Month Performance	25.83%	10.81%	5.25%	3.81%
1 Year Performance	-77.95%	62.61%	33.29%	23.90%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	1.3706 of 5 stars	$4.19 flat	$200.00 +4,673.3%	-77.9%	$6.94M	$2M	N/A	60	Gap Down
CPHI China Pharma	N/A	$0.62 -1.8%	N/A	-61.0%	$25.12M	$3.99M	N/A	250	Gap Down
MDCX Medicus Pharma	3.4409 of 5 stars	$0.44 -9.6%	$9.00 +1,940.8%	-87.7%	$24.99M	N/A	N/A	N/A	Short Interest Decrease Gap Down
TVGN Tevogen Bio	1.9459 of 5 stars	$5.85 -6.9%	$100.00 +1,608.2%	-90.7%	$24.49M	N/A	N/A	3	Gap Up
SKYE Skye Bioscience	2.0049 of 5 stars	$0.70 +3.7%	$8.50 +1,123.0%	-84.7%	$24.42M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. CPHI, MDCX, TVGN, SKYE, and MRKR

How does BioAtla compare to China Pharma?

Summary

How does BioAtla compare to Medicus Pharma?

Summary

How does BioAtla compare to Tevogen Bio?

Summary

How does BioAtla compare to Skye Bioscience?

Summary

How does BioAtla compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. CPHI, MDCX, TVGN, SKYE, and MRKR

How does BioAtla compare to China Pharma?

Which has higher valuation & earnings, BCAB or CPHI?

Is BCAB or CPHI more profitable?

Which has more risk and volatility, BCAB or CPHI?

Do analysts prefer BCAB or CPHI?

Do institutionals and insiders believe in BCAB or CPHI?

Does the media favor BCAB or CPHI?

Summary

How does BioAtla compare to Medicus Pharma?

Which has preferable earnings and valuation, BCAB or MDCX?

Is BCAB or MDCX more profitable?

Do institutionals & insiders believe in BCAB or MDCX?

Which has more risk & volatility, BCAB or MDCX?

Does the media refer more to BCAB or MDCX?

Do analysts prefer BCAB or MDCX?

Summary

How does BioAtla compare to Tevogen Bio?

Does the media prefer TVGN or BCAB?

Do institutionals & insiders hold more shares of TVGN or BCAB?

Which has more volatility & risk, TVGN or BCAB?

Which has higher earnings and valuation, TVGN or BCAB?

Do analysts recommend TVGN or BCAB?

Is TVGN or BCAB more profitable?

Summary

How does BioAtla compare to Skye Bioscience?

Is BCAB or SKYE more profitable?

Does the media refer more to BCAB or SKYE?

Do analysts recommend BCAB or SKYE?

Which has better earnings & valuation, BCAB or SKYE?

Which has more risk and volatility, BCAB or SKYE?

Do insiders & institutionals hold more shares of BCAB or SKYE?

Summary

How does BioAtla compare to Marker Therapeutics?

Do institutionals and insiders believe in MRKR or BCAB?

Do analysts rate MRKR or BCAB?

Is MRKR or BCAB more profitable?

Does the media refer more to MRKR or BCAB?

Which has preferable valuation and earnings, MRKR or BCAB?

Which has more volatility & risk, MRKR or BCAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools